Nuvation Bio Inc. NUVB
Set alert
4.59 USD -0.17 -3.57%
At close · Nov 2
4.68 +0.09 +1.96%
After hours · Nov 2, 5:14 PM ET
4.59 Day range 4.85
3.92 52-week range 9.75
- YTD
- -48.77%
- 1 year
- -12.07%
- Open
- 4.80
- Prev close
- 4.76
- Mkt cap
- 1.61B
- Vol
- 3.72M
- Avg vol
- 5.35M
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.59
- High
- 4.85
- Forward P/E
- -306.67
- Beta
- 1.73
- Short ratio
- 11.57
- Inst. own
- 67.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 5.63
- 200-d avg
- 5.40
- 1y target
- 13.00
1Y chart
Events in this range
- Nov 3, 2025Earnings: -0.16; estimate -0.17; surprise 5.88%
- Mar 2, 2026Earnings: -0.11; estimate -0.11; surprise 0%
- May 4, 2026Earnings: 0.01; estimate -0.02804; surprise 135.66%
- Aug 6, 2026Earnings: -0.15; estimate -0.14166; surprise -5.89%
- Aug 7, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 18, 2026Rating: JP Morgan · — → Overweight
- Aug 21, 2026Rating: Cantor Fitzgerald · — → Overweight
- Sep 16, 2026Rating: Wedbush · Outperform → Outperform
- Sep 16, 2026Rating: Citizens · Market Outperform → Market Outperform
- Sep 30, 2026Rating: Citigroup · — → Buy
Signals (54)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| MACD: Buy Signal | May 6, 2026 | 6 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| RSI: Oversold | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 9 months ago |
| RSI: Oversold | Jan 23, 2026 | 9 months ago |
| RSI: Oversold | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 26, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Dec 18, 2025 | 10 months ago |
| RSI: Overbought | Dec 16, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 10, 2025 | 10 months ago |
| RSI: Overbought | Dec 3, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 19, 2025 | 11 months ago |
| RSI: Overbought | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 7, 2025 | 12 months ago |
Key statistics
- Market cap
- 1.62B
- Enterprise value
- 1.43B
- Trailing P/E
- 0.00
- Forward P/E
- -306.67
- PEG ratio
- 0.00
- Price / sales
- 9.51
- Price / book
- 6.34
- EPS (TTM)
- -0.44
- Beta
- 1.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -88.19%
- Revenue (TTM)
- 169.90M
- Revenue growth
- 555.60%
- Free cash flow
- -112.11M
- Total cash
- 660.96M
- Total debt
- 416.26M
- Return on equity
- -47.81%
- Shares outstanding
- 350.12M
- Short % of float
- 29.65%
- 50-day average
- 5.63
- 200-day average
- 5.40
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 13.00 +183.2% upside
Now 4.59
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 21.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.10333.
Financials — quick view
NUVB Revenue — quarterly 31.69M
NUVB Net income — quarterly -62.84M
NUVB EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.12357 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.14166 | -0.15 | -0.01 | -5.89% |
| May 4, 2026 | Mar 31, 2026 | -0.02804 | 0.01 | +0.04 | +135.66% |
| Mar 2, 2026 | Dec 31, 2025 | -0.11 | -0.11 | 0.00 | 0.00% |
| Nov 3, 2025 | Sep 30, 2025 | -0.17 | -0.16 | +0.01 | +5.88% |
| Aug 7, 2025 | Jun 30, 2025 | -0.17 | -0.17 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | Citigroup | init | — | Buy |
| Sep 16, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 21, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 18, 2026 | JP Morgan | init | — | Overweight |
| Aug 7, 2026 | RBC Capital | main | Outperform | Outperform |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nuvationbio.com
News
- Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual Meeting
- Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
- Nuvation Bio Plans To Add Sites In Six European Countries For Its Pivotal Phase 3 SIGMA Study Of Safusidenib
- Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
- This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analysts
- Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
- Why Is Nuvation Bio Stock Gaining Thursday?
- Nuvation Bio Says FDA Approves sNDA For IBTROZI, ROS1 Inhibitor For Treatment Of Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Your note
Sign in to keep a note on NUVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANLEY DAVID C | Chief Technology Officer | Sale | Nov 18, 2025 | 24,000 |
| HUNG DAVID T | Chief Executive Officer | Purchase | Jun 15, 2025 | 59,281,100 |
| LIU DONGFANG | Officer | Sale | Apr 16, 2026 | 18,000 |
| MAKUNJE MOSES | Officer | Stock Award(Grant) | Feb 26, 2026 | 68,137 |
| MARKEL STACY | Officer | Sale | Jun 22, 2026 | 32,591 |
| MASHAL ROBERT | Director | Purchase | Jun 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.88% | 52,230,295 | 240.26M | Jun 29, 2026 |
| Blackrock Inc. | 7.87% | 27,630,837 | 127.10M | Jun 29, 2026 |
| Decheng Capital LLC | 7.39% | 25,954,439 | 119.39M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.39% | 11,919,514 | 54.83M | Jun 29, 2026 |
| Omega Fund Management, Llc | 2.30% | 8,081,089 | 37.17M | Jun 29, 2026 |
| Laurion Capital Management, LP | 2.19% | 7,697,272 | 35.41M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.04% | 17,697,414 | 81.41M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 8,849,329 | 40.71M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.86% | 6,523,172 | 30.01M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.42% | 4,985,277 | 22.93M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.30% | 4,561,397 | 20.98M | Aug 30, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.98% | 3,423,823 | 15.75M | Jul 30, 2026 |